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Abstract
Schistosomiasis is a tropical disease associated with high morbidity and mortality, currently affecting over 200 million
people worldwide. Praziquantel is the only drug used to treat the disease, and with its increased use the probability of
developing drug resistance has grown significantly. The Schistosoma parasites can survive for up to decades in the human
host due in part to a unique set of antioxidant enzymes that continuously degrade the reactive oxygen species produced
by the host’s innate immune response. Two principal components of this defense system have been recently identified in S.
mansoni as thioredoxin/glutathione reductase (TGR) and peroxiredoxin (Prx) and as such these enzymes present attractive
new targets for anti-schistosomiasis drug development. Inhibition of TGR/Prx activity was screened in a dual-enzyme
format with reducing equivalents being transferred from NADPH to glutathione via a TGR-catalyzed reaction and then to
hydrogen peroxide via a Prx-catalyzed step. A fully automated quantitative high-throughput (qHTS) experiment was
performed against a collection of 71,028 compounds tested as 7- to 15-point concentration series at 5 mL reaction volume
in 1536-well plate format. In order to generate a robust data set and to minimize the effect of compound autofluorescence,
apparent reaction rates derived from a kinetic read were utilized instead of end-point measurements. Actives identified
from the screen, along with previously untested analogues, were subjected to confirmatory experiments using the
screening assay and subsequently against the individual targets in secondary assays. Several novel active series were
identified which inhibited TGR at a range of potencies, with IC50s ranging from micromolar to the assay response limit
(,25 nM). This is, to our knowledge, the first report of a large-scale HTS to identify lead compounds for a helminthic
disease, and provides a paradigm that can be used to jump-start development of novel therapeutics for other neglected
tropical diseases.
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Introduction
Schistosomiasis, also known as bilharzia, a debilitating disease
resulting from the infection by the trematode parasite Schistosoma ssp.
(S. mansoni, S. mekongi, S. japonicum, S. haematobium, and S. intercalatum)
currently affects over 200 million people worldwide, mostly in
developing countries [1]. A large percentage of those infected exhibit
severe morbidity manifested as growth stunting, lassitude, and
cognitive impairment [2], and an estimated 280,000 people die
annually from the disease in sub-Saharan Africa alone [3]. The
primary route of infection is via unsafe river and lake water, which is
widely used in sub-Saharan Africa and Southeast Asia, among other
regions, for irrigation, drinking, cooking, and bathing. Larval
parasite forms (residing in and released by snails) can penetrate the
skin of people contacting the water. The lifecycle of Schistosoma is
exceedingly complex, with the parasite going through a number of
stages both outside and inside the human host. Once inside humans,
it can survive for years, even decades [4].
The need to control schistosomiasis is acute and efforts have
been ongoing for years on three main fronts: prevention (via
establishment and maintenance of sources of safe potable water),
development of a vaccine, and use of drugs to treat the infection
[1]. Although the number of schistosomiasis cases worldwide is
indeed stunning, the number of drugs available to treat the disease
is surprisingly small. Earlier in the 20
th century, schistosomiasis
was treated with highly toxic antimonial compounds, of which the
most common was potassium antimonyl tartrate (PAT, tartar
emetic). During the past three decades the only drug used against
the infection is praziquantel, which is administered orally, is stable,
effective against all major schistosome species in a single dose, and
relatively inexpensive [5,6]. However, because of high reinfection
rates, praziquantel must be administered on an annual or semi-
annual basis. While its exact mechanism of action is unclear,
praziquantel is thought to affect the parasites by disrupting
calcium homeostasis [7,8]. Preliminary reports of praziquantel-
resistant cases, and the generation of praziquantel-resistant
parasites in the laboratory [9–11] highlight the need for new
drugs to treat the disease. Artemisinin has shown promise as a new
drug for schistosomiasis [12] although its use for schistosomiasis
may be restricted in areas of malaria transmission so that its use as
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artemisinin, the 1,2,4-trioxolanes, show promise and potential
selectivity, but these, like the parent compound, are significantly
less active against adult schistosome parasites [13]. Oxamniquine,
used extensively in Brazil in the past, is effective only against S.
mansoni and resistance has been reported further reducing its
potential value in schistosomiasis control [10].
Studies of the schistosome life cycle have focused on the fact it can
survive for decades in the blood stream of the human host without
being severely affected by the immune system and the associated
assault by various reactive oxygen species (ROS). Since schistosomes
do not have catalase to degrade hydrogen peroxide [14], other
mechanisms must exist within the parasite to degrade ROS. Two
uniquely positioned S. mansoni enzymes have been recently described
that seem to act in concert to provide an effective antioxidant
‘‘firewall’’. Thioredoxin glutathione reductase (TGR) is a multifunc-
tional selenocysteine-containing enzyme that catalyzes the intercon-
version between reduced and oxidized forms of both glutathione
(GSH) and thioredoxin (Trx), which are major contributors to the
maintenance of redox balance in eukaryotes [15]. In contrast,
humans possess two distinct enzymes, glutathione reductase (GR)
and thioredoxin reductase (TrxR), which specifically recognize GSH
and Trx as substrates, respectively [16]. The apparent replacement
of two human enzymes by one dual-specificity worm enzyme has
created a metabolic and regulatory bottleneck in which the
inactivation of a single target, TGR, might have an enhanced
deleterious effect on both the maintenance of parasite’s redox
balance and on its ‘‘antioxidant firewall’’. Indeed, recent small
molecule inhibition and RNA interference experiments have shown
that inactivation of TGR has profound effects on S. mansoni survival
rates both in culture and in infected mice [17]. Another component
of the S. mansoni ‘‘firewall’’ are the peroxiredoxins (Prx), which are
responsible for catalyzing the electron transfer to the main ROS
agent hydrogen peroxide and, uniquely for schistosomes, from both
GSH and Trx [18]. Thus, when TGR and Prx operate in concert,
NADPH reducing equivalents are essentially transferred via TGR-
catalyzed reaction to the oxidized forms of either Trx or GSH, while
Trx or GSH in turn transfer reducing equivalents to hydrogen
peroxide via Prx-catalyzed reactions (Figure 1).
Such improved understanding of the organisms responsible for
neglected tropical diseases (NTDs) presents opportunities for new
drug development. However, private-sector biopharmaceutical
interest in NTDs has traditionally been limited due to high risk
and low expected return-on-investment of these projects, though
this is beginning to change with the advent of increased
philanthropic and public-private-government partnership funding
[19]. A significant problem that remains, however, is the
significant gap in technologies, expertise, and cultures between
academic and biopharmaceutical organizations [20]. At the US
National Institutes of Health (NIH), the NIH Roadmap Molecular
Libraries Initiative (MLI) was started in 2004 in part to address
this problem. The MLI provides academic investigators with the
pharma-scale infrastructure and technologies necessary to discover
both chemical probes of physiology, and starting points for
development of novel therapeutics for the rare and neglected
diseases that are of less interest to the pharmaceutical sector [21].
The TGR/Prx work described here is the result of the first project
officially accepted by the MLI in 2005. Since inhibiting either TGR
or Prx can potentially lead to schistosome death [22], we chose to
screen both enzymes in one assay as a reconstituted redox cascade.
While TGR and Prx2 can be assayed individually, the separate
assays are relatively less robust. TGR can be assayed in a relatively
simple colorimetric assay by following the catalytic reduction of
DTNB (5,59 dithiobis(2-nitrobenzoic acid), Ellman’s reagent) by
NADPH; Prx2 at present can only be assayed with thioredoxin as a
substrate together with TGR or thioredoxin reductase, or in a
coupled reaction involving yeast glutathione reductase, and HTS-
compatible assays [23] have yet to be developed [17,18,24]. By
performing the high-throughput screen against both enzymes
(present at equivalent levels in the assay), we were able to address
both novel targets simultaneously while also combining target
deconvolution and confirmation at the post-screen stage. In this
report, we describe the miniaturization to 1536-well density of a
cuvette-based assay for the TGR/Prx2 cascade which utilizes as a
quantitative measure the decrease in fluorescence of the consumed
NADPH substrate, the performance of a quantitative high-
throughput screen (qHTS) [25] against 71,028 discrete compounds,
and the initial characterization of several novel series of inhibitors.
The application of qHTS, in which each library compound is
assayed at a range of concentrations to generate a dose-response
profile, facilitated triaging of actives for the purpose of structure-
activity relationship (SAR) analysis and lead expansion.
Materials and Methods
Reagents
Nicotinamide adenine dinucleotide phosphate (NADPH), glu-
tathione reduced form (GSH), hydrogen peroxide, Tween-20 and
Figure 1. TGR/Prx2 assay principle.
doi:10.1371/journal.pntd.0000127.g001
Author Summary
Schistosomiasis, also known as bilharzia, is a tropical
disease associated with high morbidity and mortality,
currently affecting over 200 million people worldwide.
Praziquantel is the only drug used to treat the disease, and
with its increased use the probability of developing
resistance has grown significantly. The Schistosoma para-
sites can survive for up to decades in the human host due
in part to a unique set of antioxidant enzymes that
continuously degrade the reactive oxygen species pro-
duced by the host’s innate immune response. Two
principal components of this defense system, thiore-
doxin/glutathione reductase (TGR) and peroxiredoxin
(Prx2), have been recently identified and validated as
targets for anti-schistosomiasis drug development. In
search of inhibitors of this critical redox cascade, we
optimized and performed a highly miniaturized automated
screen of 71,028 compounds arrayed as 7- to 15-point
dilution sets. We identified novel structural series of TGR
inhibitors, several of which are highly potent and should
serve both as mechanistic tools for probing redox
pathways in S. mansoni and as starting points for
developing much-needed new treatments for schistoso-
miasis. The paradigm presented here effectively bridges
the gap between academic target identification and the
first steps of drug development, and should be applicable
to a variety of other important neglected diseases.
qHTS for Inhibitors of S. mansoni Redox Cascade
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Aldrich. DMSO Certified ACS Grade was from Fisher. The
screening assay was performed in 100 mM phosphate buffer
pH 7.4 containing 10 mM EDTA and 0.01% Tween-20.
Preparation of Recombinant S. mansoni TGR and Prx2
Recombinant TGR with a fused bacterial-type SECIS element
was expressed in the Escherichia coli strain BL21(DE3) (Invitrogen)
in the presence of pSUABC in LB medium supplemented with
20 mM flavin adenine dinucleotide following conditions for
optimal selenoprotein expression as described [17]. TGR was
purified to homogeneity on an adenosine 29,59-diphosphate
agarose (Sigma) column equilibrated with TE buffer as described
[17]. TGR concentration was determined from the flavin adenine
dinucleotide absorption (e463=11.3 mM
21cm
21). The pure
protein was dialyzed against PBS and stored at 280uC.
Recombinant Prx2 in pRSETA was expressed in E. coli strain
BLR(DE3)pLysS (Novagen) as described [18]. Briefly, after a 3-hr
induction in 1 mM IPTG, cells were sonicated in 5% mono-
thioglycerol (3-mercapto-1,2-propanediol) in 10 mM imidazole,
0.07 M Na2HPO4, 0.01 M NaH2PO4, and 0.15 M NaCl, pH 7.4.
The supernatant was filtered and Prx2 was purified to homoge-
neity on a His Trap column (Amersham Biosciences). Protein
purity was verified by SDS-PAGE. The purified protein was
dialyzed against PBS and stored at 280uC until used.
Compound library
The 71,028 member library comprised two main subsets:
59,692 compounds from the NIH Molecular Libraries Small
Molecule Repository (www.mli.nih.gov), prepared as 10 mM stock
solutions in 384-well plates and delivered by Biofocus DPI (South
San Francisco, CA, http://mlsmr.glpg.com/MLSMR_Home-
Page/), and NCGC internal exploratory collection of approxi-
mately 11,336 compounds which consisted of several commer-
cially available libraries of known bioactives (1280 compounds
from Sigma-Aldrich (LOPAC1280 library), 1120 compounds from
Prestwick Chemical Inc. (Washington, DC), 980 compounds from
Tocris (Ellisville, Missouri), 280 purified natural products from
TimTec (Newark, DE), 1980 compounds from the National
Cancer Institute (the NCI Diversity Set)), 1408 National Institute
of Environmental Health Sciences collection of known toxic
compounds, as well as collections from other commercial and
academic collaborators (three 1000-member combinatorial libraries
from Pharmacopeia (Cranbury, NJ), 718 compounds from Boston
University Center for Chemical Methodology and Library Devel-
opment, 96-member peptide library from Prof. Sam Gelman’s lab,
University of Wisconsin, Madison, and 474 compounds from the
University of Pittsburgh Center for Chemical Methodology and
Library Development). The compound library (7 mL each in 1536-
well Greiner polypropylene compound plate) was prepared as
DMSO solutions at initial concentrations ranging between 2 and
10 mM. Plate-to-plate (vertical) dilutions and 384-to-1536 compres-
sions were performed on Evolution P3 dispense system equipped
with 384-tip pipetting head and two RapidStak units (Perkin-Elmer,
Wellesley, MA). Additional details on the preparation of the
compound library are provided in Inglese et al [25].
Control plate
Titration of the known inhibitor PAT (PubChem CID6328158)
was delivered via pin transfer from a separate plate to the lower
half of column 2 of each assay plate. The starting concentration of
the control, dissolved in 1:1 DMSO:water, was 1 mM, followed by
five-fold dilution points in duplicate, for a total of eight
concentrations.
qHTS protocol
Three mL of reagents (100 mM NADPH in columns 3 and 4 as
negative control and 100 mM NADPH, 42 nM TGR, 700 mM
GSH, 83 nM Prx2 mixture in columns 1, 2, 5–48) were dispensed
into 1536-well Greiner black assay plates. Compounds and control
(23 nL) were transferred via Kalypsys PinTool equipped with
1536-pin array (10 nL slotted pins, V&P Scientific, Palo Alto, CA).
The plate was incubated for 15 min at room temperature, and
then a 1 mL aliquot of 400 mM NADPH/700 mM GSH was
added, immediately followed by a 1 mL aliquot of 2.5 mM H2O2
to start the reaction. The plate was transferred to ViewLux high-
throughput CCD imager (Perkin-Elmer, Wellesley, MA) where
kinetic measurements (16 reads, one read every 30 sec) of the
NADPH fluorescence decrease were acquired using 365 nm
excitation/450 nm emission filter set. During dispense, the reagent
bottles were kept submerged into 4uC recirculating chiller bath to
minimize degradation. All screening operations were performed
on a fully integrated robotic system (Kalypsys, San Diego, CA)
containing one RX-130 and two RX-90 anthropomorphic robotic
arms (Staubli, Duncan, SC). Library plates were screened starting
from the lowest and proceeding to the highest concentration.
Vehicle-only plates, with DMSO being pin-transferred to the
entire column 5–48 compound area, were inserted uniformly at
the rate of approximately one plate for every 50 library plates in
order to monitor for and record any shifts in the background.
Analysis of qHTS data
Time course data were collected on per-assay plate basis and
were processed using in-house developed software. For each
sample and at each individual concentration, 16 time points were
processed using ordinary least squares regression to determine
slope and intercept of linear fit. Additionally, a difference (delta) of
last and first time point was generated for each time course. For
activity calculations, delta values were chosen while the calculated
slope, intercept, and the raw time-course data were stored in the
database. Screening data were corrected and normalized and
concentration–effect relationships derived by using the GeneData
Screener software package (Basel, Switzerland). Percent activity
was computed from the median values of the uninhibited, or
neutral, control (48 wells located in column 1 and one-half of
column 2) and the no-enzyme, or 100% inhibited, control (64
wells, entire columns 3 and 4), respectively. For assignment of
plate concentrations and sample identifiers, ActivityBase (ID
Business Solutions Ltd, Guildford, UK) was used for compound
and plate registrations. An in-house database was used to track
sample concentrations across plates. Correction factors were
generated from the DMSO plate data and applied to each assay
plate to correct for systematic errors in assay signal potentially
resulting from issues with reagent dispensers or decrease in enzyme
specific activity. A four parameter Hill equation [26] was fitted to
the concentration-response data by minimizing the residual error
between the modeled and observed responses. Outliers could be
identified and masked by modeling the Hill equation and asking if
the differences exceeded those expected from the noise in the
assay.
The curve classification used is the same as described in Inglese
et al. (2006) [25]. Briefly, concentration-response curves are placed
into four classes: Class 1 contains complete concentration-response
curves showing both upper and lower asymptotes and r
2 values
.0.9. Class 2 contain incomplete concentration-response curves
lacking the lower asymptote and show r
2 values .0.9. Class 3
curves are of the lowest confidence as they are defined by a single
concentration point where the minimal acceptable activity is set at
3 SD of mean. Curves are classified as negative or positive
qHTS for Inhibitors of S. mansoni Redox Cascade
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inhibition) or increase (apparent activation). Finally, Class 4
contains compounds that do not show any concentration response
curves and are therefore classified as inactive.
A workflow was developed to facilitate a systematic approach in
providing exhaustive analysis of structure activity relationships
(SAR). First, a set of criteria used to define rules of determining an
active set of compounds for the assay. These include decisions on
inhibitors and activators, selectivity and counter screen informa-
tion, curve class ranges, background fluorescence, etc. For this
assay, compounds that showed signal activation (positive curve
classes) were regarded as active due to fluorescence and were thus
filtered out. The criteria are implemented as filters that are applied
to rapidly define a core active set of compounds. This process
eliminates many positive series that appear to have SAR and show
reasonable titration response curves, but are not of biological
relevance to the targets [23]. Next, the range of curve classes was
limited to 21 through 23 to select for compounds showing signal
decrease. Once an active set of compounds was identified,
hierarchical agglomerative clustering with a 0.7 Tanimoto cutoff
was performed using Leadscope (Leadscope Inc., Columbus, OH)
fingerprints, which are ideally suited for two-dimensional scaffold-
based based clustering [27]. For each cluster, maximal common
substructures (MCS) were extracted, and a manual step of
trimming the MCSs was performed to create a list of scaffolds.
This clustering step typically has overlapping compounds and thus
can lead to overlapping MCSs. This list of trimmed scaffolds is
abridged to a canonical set. Each scaffold is then represented as a
precise definition to indicate number of attachments, ring size
variability, etc. All filters were then relaxed to include all negative
assay data. In the initial clustering, a set of singletons was found.
These compounds were reported upon separately with their
individual activity profiles. SAR series and singletons were finally
ranked by their activity profile.
Follow-up testing of primary actives and analogs
Screening actives and analogues sourced as powders from the
respective original suppliers (Sigma-Aldrich, NCI, Asinex, Chem
Bridge, Tocris, Ambinter, and ChemDiv) were dissolved in
DMSO to produce 10 mM initial stock solutions. The samples
were then serially diluted row-wise in 384-well plate in twofold
steps for a total of 24 concentrations, from 10 mM to 1.2 nM.
Upon completion of the 24-point dilution, solutions from two 384-
well plates were transferred to duplicate wells of 1536-well
compound plate. The last two rows of the 1536-well plate did
not contain any test compound and were reserved for placement of
positive and negative controls. The assay protocol for confirmation
was essentially the same as that described in the qHTS protocol
section. A Flying Reagent Dispenser (FRD, Aurora Discovery,
presently Beckman-Coulter) [28] was used to dispense reagents
into the assay plates.
Target-deconvolution assays
Assays were performed at 25uC in 0.1 M potassium phosphate,
pH 7.4, 10 mM EDTA using 100 mM NADPH. The Prx2 assay
was based on the reduction of H2O2 by Prx2 in the presence of
GSH measured by the reduction of the GSSG produced in a
coupled assay with yeast glutathione reductase monitored by
observing the decrease in A340 nm due to consumption of NADPH
(e340 nm=6.22 mM
21 cm
21) during the first three minutes [18].
The activity of TGR was determined with 3 mM 5,59 dithiobis(2-
nitrobenzoic acid) (DTNB, Ellman’s reagent) [29] following the
increase in A410 nm due to the production of 2-nitro-5-thiobenzoic
acid (e412 nm=13.6 mM
21 cm
21) [17,18].
Results
Assay Principle, Miniaturization, and Optimization
The assay was initially developed and optimized using a
spectrophotometer by following the decrease in absorbance at
340 nm associated with the consumption of NADPH substrate.
During these studies, the main parameters of the assay, such as buffer
conditions, concentration of each enzyme and substrate, DMSO and
detergent tolerance, were tested and optimized (data not shown). The
optimized assay utilized TGR and Prx2 at final concentrations of
25 nM and 50 nM, respectively. The substrates’ final concentrations
were 200 mM NADPH, 700 mM GSH, and 500 mMH 2O2.T h e
Table 1. S. mansoni redox cascade qHTS protocol.
Step Parameter Value Description
1 Reagent 3 mL Enzyme and no-enzyme control solutions
2 Library Compounds 23 nL 57 mM to 2.9 nM titration series
3 Controls 23 nL PAT titration
4 Incubation Time 15 min Compound interaction with targets
5 Reagent 1 mL Second equivalent of NADPH
6 Reagent 1 mLH 2O2 Substrate addition to initiate reaction
7 Assay Readout 365/450 nm Fluorescence intensity kinetic read
Step Notes
1 Black solid bottom plates, single-tip dispense, enzyme in columns 1, 2, 5–48, no-enzyme in columns 3 and 4.
2 Pintool transfer of library samples to columns 5–48 of the assay plate.
3 Pintool transfer of PAT titration to lower half of column 2.
4 Room temperature incubation in auxiliary hotel.
5 Solution of 400 mM NADPH and 700 mM GSH.
6 Hydrogen peroxide addition via 8-tip dispense.
7 ViewLux CCD imager, one read per 30 seconds for 8 min.
doi:10.1371/journal.pntd.0000127.t001
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appropriate adjustment of stock concentrations of enzymes and
substrates to reflect the volumes being combined. For example, the
assay was started by the dispense of the two enzymes at 5/3 of their
final concentration to account for the well volume increasing from 3
to 5 mL, while the hydrogen peroxide substrate was delivered as 56
solution to account for its dilution (1 mLt o5mLf i n a lv o l u m e ,s e e
Materials and Methods, Table 1). All three types of reagents
(enzymes, second aliquot of NADPH, and hydrogen peroxide) were
tested and were shown to be stable overnight at 4uC, a requirement
for the execution of an uninterrupted fully automated screen on the
Kalypsys robotic system (Figure 2). In addition, the signal being
monitored was changed from absorbance to fluorescence in order to:
1) improve the signal strength, as UV-shifted absorbance assays are
generally difficult to scale to a 1536-well density (due to the
combination of low extinction coefficient and short path length), and
2) minimize the quenching and inner-filter effects of a multitude of
compounds which absorb light in this wavelength region [23].
In a typical uninhibited reaction in 1536-well plate, the well
fluorescence changed from 370 relative fluorescence units (RFU)
to 180 RFU within an eight-minute window. This resulting
outcome, if registered as an end-point reading, and assuming zero
change in the background, would yield a signal-to-background
(S:B) ratio of only approximately 2.1. Therefore the assay was
further improved by modification of the type of signal collected
from single end-point to multipoint kinetic read. Thus, for each
plate the reaction progress was recorded for 8 minutes at the rate
of one fluorescence read every 30 seconds. Such kinetic mode data
acquisition not only secured a more robust assay signal but
minimized the interfering effects of dust and mildly fluorescent
compounds (see Discussion).
qHTS Performance
In total, 453 assay plates were screened in one uninterrupted
robotic run lasting approximately 75 hours. Dispenser malfunc-
tion resulted in deteriorated signal in two plates and since the issue
was noted in real time, the two 7-point libraries containing the
problematic plates, plus two DMSO-only plates, were scheduled
for re-screening immediately after the end of the main run. In this
manner, the re-screened series were tested using the same batch of
reagents as last series of the main screen. The assay performed
robustly, yielding an average Z9 value of 0.76 [30]. Overall, the Z9
factor remained flat with the screen progression, with minor shifts
tracking the introduction of new batches of the two enzymes
(Figure 3A). The intraplate PAT control titration was stable
throughout the screen progression, resulting in average IC50 of
1468 nM and minimum significant ratio of 4.03 (Figure 3B) [31].
Each library compound was tested at a minimum of seven
concentrations, ranging from 57 mM to 2.9 nM, and for each
well, 16 time points were collected for a total of 9,562,432 data
points. The screen and the preceding optimizations and
validations consumed approximately 4.7 mg of TGR and 10 mg
of Prx2. The overall materials cost of the screen (not including the
cost of protein production) was approximately $5,200, or 0.85
cent per sample well, with approximately 80% of the costs
associated with the assay microtiter plates and 15% attributed to
NADPH.
Analysis of qHTS data
Unlike traditional HTS, qHTS provides concentration respons-
es for all the compounds screened and allows determination of an
AC50 value, defined as the half-maximal activity concentration, for
each compound in the primary screen. In qHTS concentration
response curves are classified as belonging to one of four groups
based on efficacy (response magnitude), presence of asymptotes,
and goodness of fit of the curve to the data (r
2). For the present
screen, the activity associated with each well was computed from
the change in fluorescence intensity over the time-course
measurement period, normalized against control wells. In
addition, the y-intercept of the reaction progress plot, typically
equal to fluorescence at the first time point, was stored in the
database and was used to further scrutinize purported actives.
Compounds which showed activity but also had elevated y-
intercept values were flagged as potential fluorescent artifacts.
Figure 3. qHTS performance. Z9 trend (A) and intraplate control titrations (duplicate curves per plate) (B) as a function of plate number.
doi:10.1371/journal.pntd.0000127.g003
Figure 2. Screening reagents’ stability as a function of storage
time. Bottles containing buffer, enzyme, and substrate stock solutions,
respectively, were prepared and kept at 4uC. At the selected time
points, the bottles were connected to a liquid dispenser and the assay
was performed as described in Methods. Signal-to-background ratio
(S:B) and Z9 factor were computed as the average of 32 wells.
doi:10.1371/journal.pntd.0000127.g002
qHTS for Inhibitors of S. mansoni Redox Cascade
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Analysis of the qHTS results revealed 39 actives characterized
by full concentration-response curves and IC50 values of better
than 10 mM. After exclusion of antimony-containing compounds,
as well as various mercury- and other heavy metal-containing
molecules, the following series and singletons were selected for
further studies after SAR analysis (Figure 4): oxadiazole 2-oxides (5
actives out of 29 analogues in collection, IC50 potency range
between 8 mM and inactive), phosphinic amides (two compounds
in the collection, one inactive and one active at 37 nM),
phosphoramidite (singleton active, IC50 of 560 nM), and iso-
xazolone (singleton active, IC50 of 530 nM). In addition, a weaker
series, quinolinyl sulfonamides (8 actives out of 47 total analogues
in collection, IC50 potency range between 0.6 mM and inactive),
was identified but noted to contain a number of both active and
inactive members which were strongly fluorescent as judged by the
extreme intercept values recorded during the screen. In contrast,
neither the oxadiazole series nor the singleton actives exhibited
any detectable autofluorescence (Figure 5).
In addition to inhibitors, the screen yielded a number of
apparent activators, that is, compounds for which the increase in
concentration led to a fluorescence intensity change greater than
that of the neutral control. Upon examination of the time-course
plots associated with these activators it became evident that the
signal enhancement originated from high starting fluorescence
which decreased during the observation window and in many
cases entirely obscured the assay-driven NADPH fluorescence
change (Figure 5C). While some of these compounds might be
fluorescent substrates for either TGR or Prx2, which get converted
to non-fluorescent products, a large number might simply be
reactive towards any one or more components of the assay milieu
(GSH, NADPH, and/or H2O2). As such, their confirmation and
mode of action is subject of separate study.
Series expansion and confirmation
In order to further confirm the qHTS actives and to expand the
actives series, especially around the otherwise attractive singletons,
powder samples were purchased from the original compound
vendors and processed as described in the Methods. In addition to
qHTS-identified compounds, untested analogues of the singletons
were also procured in an attempt to support the singleton findings
by the generation of small SAR series. The comparison of qHTS
results, where applicable, and re-test results from independently
acquired powder samples are shown in Figure 4, first and second
data columns, respectively. The overall confirmation rate was
excellent with the exception of the sulfonamide series of actives,
which showed wide shifts between qHTS and confirmatory assay
(results not shown). The apparent lack of confirmation for this series
was consistent with the aberrant fluorescent values associated with
many of its members. An analogue series built around a lower-
potency benzoindolone singleton (NCGC00038549, IC50 of
3.9 mM) failed to yield activity against the screening assay and
against both TGR and Prx2 individual assays. The original activity
of that singleton was therefore deemed an artifact.
Gratifyingly, the previously-untested analogues of the phos-
phinic amides (compounds 1–4), phosphoramidite (13–16), and
isoxazolone (10–12) actives all showed activity with various
degrees of potency, supporting and expanding the qHTS findings.
Specifically, the ‘‘gap’’ in potency between the highly active 3
(NCGC00042730, qHTS IC50 of 37 nM, confirmed at 25 nM on
re-test) and the inactive distant analogue 4 (NCGC00064648)
was filled partially by the newly-acquired analogues 1
(NCGC00093512, IC50 of 247 nM) and 2 (NCGC00093512,
IC50 of 23 mM). Similarly, increased potency was achieved by the
addition of analogues to the phosphoramidite (from a singleton
IC50 of 0.5 mM to a range of 0.2–2 mM) and the isoxazolone (from
a singleton IC50 of 0.5 mM to a range of 0.1 mMt o9mM).
Target deconvolution
After establishing the activities of primary hits and new analogues
against the screened dual-enzyme system, the compounds were
further subjected to target deconvolution experiments. When tested
against Prx2 in a GR-coupled hydrogen peroxide reduction assay
noneoftheselectedcompoundsshowedactivityuptothe50 mMto p
concentration tested (and by extension, none were active against
GR, an enzyme related to TGR). Prx2 was thereforeruled out as the
target of any of the actives identified in the screen. Results from the
TGR assayare showninthelastcolumnof Figure4. Themajorityof
active compounds demonstrated approximately the same, and in
some instances improved (most notably with 7 and 8), potency
against the isolated TGR as they did against the dual-enzyme
system. These results not only confirm the initial findings from the
screen, but also furthersupportthe hypothesisof TGR being the sole
target of these actives. Additionally, all members of the sulfonamide
series were inactive against both Prx2 and TGR, further
strengthening the argument that their initial classification as actives
was due to fluorescence interference originating from either the
compound, impurities, or product(s) of its breakdown.
Discussion
The stability, relatively low cost, and effectiveness of prazi-
quantel has practically created a dependency on this single drug to
treat schistosomiasis. Both the success of praziquantel and the
general lack of incentives for large pharmaceutical companies to
embark on research and development in the area of tropical
diseases have led to a fairly dry pipeline for both drugs to treat
schistosomiasis and basic research tools to study the lifecycle of this
important parasite. To this end, we implemented a highly-
miniaturized automated screen of the NCGC small molecule
collection in an attempt to identify novel inhibitors of S. mansoni
TGR or Prx2, both of which have been recently validated as
crucial S. mansoni enzymes and have been proposed as targets for
drug development. Prior to HTS adoption, the assay employed
monitoring NADPH absorbance. While such a format is very
convenient, offering fast access to kinetic data via the use of
standard spectrophotometers, measuring absorbance in the UV
region in 1536-well density is rarely practical. A significant fraction
of organic molecules, as well as dust and buffer components,
absorb in the 350 nm range, thereby introducing unacceptably
high levels of interference. Additionally, the relatively low
extinction coefficient of NADPH coupled with the short optical
path length of the plate well significantly reduces the signal
available for detection. Because NADPH is naturally fluorescent,
emitting at ,450 nm, while its oxidized counterpart NADP is not,
we switched the detection platform for the coupled reaction from
absorbance to fluorescence, a step that parallels the application of
profluorescent substrates in assays for phosphatases and proteases
[23], with the main difference being the fluorescence change
trending from high to low in this reaction.
Because of the anticipated fluorescence interference from
compound library members in this blue-shifted detection region
and because the output generated from NADPH is not very strong
(due to the combination of low extinction coefficient and quantum
yield), we further modified the detection format of the assay to
measure the reaction progress in kinetic mode as opposed to
collecting a single end-point read. While kinetic, or time-course,
measurements are routinely performed during assay development
qHTS for Inhibitors of S. mansoni Redox Cascade
PLoS Neglected Tropical Diseases | www.plosntds.org 6 2008 | Volume 2 | Issue 1 | e127Figure 4. Structure and potency (IC50 in mM) of actives and series expansion analogues. ‘qHTS’ lists the IC50 values obtained from the
initial high throughput screen of the collection; ‘confirmation’ represents the IC50 values obtained using the identical assay as in the qHTS from the
compounds identified in qHTS and expansion series; ‘TGR Assay’ is the IC50 values obtained in an assay of TGR activity using DTNB as a substrate. NS,
not screened (compound not in the screening collection), ND, not determined, NA, not applicable. IC50 values greater than 50 or 57 mM signify lack of
fitted curve through the dose-response data, i.e. flat response within the range tested.
doi:10.1371/journal.pntd.0000127.g004
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automated large-collection screens is not trivial. Unless the
reaction under study is slow, only a fast-scanning reader or
whole-plate imager (such as the ViewLux) can allow positionally-
unbiased and rapid repeated measurements of 1536-well plates
without significantly slowing down the overall plate processing
speed. The collection of at least a two-point time course allows the
effects of dust and fluorescent but otherwise inert library members
to be subtracted out to reveal the true reaction course. Because the
first time-point values (when the enzymatic reaction has produced
minimal amount of product) associated with each compound well
are stored in the database, a further analysis can be performed to
flag interfering fluorescent library members [32]. An added benefit
is that the signal-to-background computed from kinetic measure-
ments significantly improves relative to end-point data and thus
allows screening under conditions of low substrate conversion [33].
While in this screen we collected a total of 16 points per well,
further optimization of the assay conditions could have resulted in
shortened read time without the loss of sensitivity.
The primary screen against the TGR/Prx2 cascade was
performed in Quantitative High Throughput Screening (qHTS)
format. In qHTS, every compound in the collection is tested over a
range of concentrations, spanning from tens of micromolar to low
nanomolar, to generate a complete concentration-response profile.
As such, qHTS is best described as high throughput pharmacology,
since as a resultof its application, not onlyarepotencies and efficacies
assigned to each active compound but also false positives and
negatives due to outliers associated with individual concentration
responses are easily identified in the context of titration. Additionally,
due to the built-in replicates in the testing of each compound, the
need for laborious and infrastructure-intensive cherry-picking,
original-result replication, and dose-response characterization are
eliminated. In our present assay, the application of qHTS enabled us
to not only skip the direct confirmation steps but also to combine the
Figure 5. Example time-course plots derived from the primary screen, followed to the right by the corresponding concentration-
response curves. (A, B) Non-fluorescent inhibitors, compounds 3 and 14; the decrease in fluorescence is inhibited at increasing compound
concentrations while the starting fluorescence remains constant. (C) An example of an apparent activator (Ofloxacin): a highly fluorescent compound
which appears to be reacting with one or more components of the assay. Four concentrations out of seven or fifteen are plotted in each of the time
course plots for clarity; &, 3.2 nM; m, 16 nM; %,1 0mM; n,5 0mM.
doi:10.1371/journal.pntd.0000127.g005
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expansion around limited SAR or singletons. In traditional single-
concentration screening, singleton actives are necessarily treated with
great caution given statistical uncertainties. In this study, the qHTS
paradigm allowed us to confidently select the potent phosphinic
amide, isoxazolone and phosphoramidite singletons 3, 10 and 14
(Figure 4) for further testing and that selection was later validated by
the excellent confirmation of those actives and the successful
expansion of the series. Separate, but equally important, is the aspect
of reliability and robustness of screening data. qHTS, with the
combination of dose-survey and replicate points, indeed offers
uniquely rich and robust data sets for deposition in recently
established public databases, such as PubChem. Additionally, in
order to minimize the interfering effect of promiscuous inhibitors
acting via colloidal aggregate formation [34,35], we included
detergent in the assay buffer.
Throughout the entire screen, the assay performed in a robust
manner, yielding an average Z9 value of 0.76. Overall, the Z9
factor remained flat with the screen progression, with minor shifts
tracking the introduction of fresh batches of enzyme. The
availability of periodically computed Z9, signal-to-background,
and activity heatmaps throughout the screen progression, made
possible by the development of fast data-processing tools in-house,
significantly improved our response time when screen complica-
tions arose. For example, the dip in Z9, also accompanied by noisy
activity heatmap (not shown), was noted almost in real-time and
this allowed the appropriate concentration series to be scheduled
for re-run within the same screening session.
Figure 3B presents a cumulative plot of all intra-plate concentra-
tion-response curves of PAT throughout the entire screen. The
narrow range of observed IC50 values serves as a further indication
that the screen performed robustly from a standpoint of enzyme
activity and responsiveness to inhibition. The titration curve
displayed stability throughout the screen despite the fact that PAT
is only partially soluble in DMSO and required formulation in high-
percent water, leading to concerns about evaporation-related
variability. Analyzing the trend in the intra-plate control as a
function of screen progression allows one to ascertain the ‘health’ of
the screening system as a whole, because the variations or dramatic
shifts in potency of the control could be due to not only a
deterioration in enzyme quality (which could otherwise be detected
from an shift in the S:B value) but also to problems with the pintool
delivery of compounds. The absence of abrupt and significant shifts
in the intra-plate control curve allows us therefore to conclude that
the compound transfer remained uniform throughout the screen.
The screen identified numerous arsenic, antimony, mercury, and
other heavy-metal containing compounds (data not shown; for
complete set of actives, see PubChem, AID 448). The antimony-
containing compounds were largely similar to PAT and were
therefore expected to be identified by this assay. Likewise, Hg-
derivatives inhibited the enzymes strongly, as expected. While PAT
and the gold-containing drug auranofin had been shown to inhibit
thioredoxin reductase and TGR [17,36,37], and while more recently
arsenic trioxide has shown anticancer activity and its effect has been
ascribed to Trx reductase-mediated apoptosis [38], we restricted our
analysis to novel nonmetal-containing compounds, primarily due to
the fact that heavy metal-containing compounds frequently exhibit
non-selective inhibition against a broad panel of enzymes and
because nonmetal novel chemotypes against these previously-
unscreened targets appeared to offer the greatest promise for
optimizing potency and specificity. In this regard, the screen was
successful, having resulted in identification of several distinct series of
TGRinhibitors.It is noteworthy that the top activesfrom someseries,
such as the phosphinic amide 3, oxadiazole 2-oxide 7,a n d
isoxazolone 11,y i e l d e dI C 50 values close to the final TGR assay
concentration (25 nM in qHTS and confirmation and 15 nM in the
TGR individual assay), thus approaching the limit of the detectable
potency range. In terms of the lead actives there are several
interesting points. For instance, the role of the benzothiazole
heterocycle within the phosphinic amide series is apparently critical
for inhibition as illustrated by the comparative values of analogues 3,
active and containing a benzothiazole moiety, and 4,i n a c t i v ea n d
devoid of benzothiazole (Figure 4). The oxadiazole series contains
several symmetric heterocyles (a function of their synthetic ease) and
are known NO donors [39,40]. The presence of two phosphorus
based small molecules may well relate to the presence of a
selenocysteine in TGR and the relative electrophilic nature of this
functionality. Studies to expand upon selected lead actives and further
understand their mechanism of action are currently underway.
Furthermore, in the Prx2 deconvolution assay, none of the top actives
were found to inhibit GR, an enzyme closely related to TGR. This
suggests that selective activity against the parasite (which lacks GR)
and less toxicity to humans (who have GR) can be achieved.
In summary, a kinetic-based qHTS against a pair of novel,
validated targets from S. mansoni allowed fast and reliable
identification of compounds active against this critical redox
cascade. We have identified several novel structural series of TGR
inhibitors, several of which are highly potent and should serve
both as mechanistic tools for probing the redox balance in S.
mansoni, and starting points for developing medicinal leads for
much-needed new treatments for schistosomiasis. The work
presented here effectively bridged the gap between academic
target identification and the first steps of drug development for an
important neglected disease [20]. Generalization of this paradigm
to other neglected diseases could prove be a powerful approach to
catalyzing new therapeutic development for NTDs.
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